LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

LLY

1,095.3

-2.56%↓

JNJ

225.25

-2.39%↓

ABBV

215.55

-1.4%↓

UNH

380.26

-0.52%↓

MRK

119.03

-0.46%↓

Search

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

31.32 0.03

Resumen

Variación precio

24h

Actual

Mínimo

31.17

Máximo

31.32

Métricas clave

By Trading Economics

Ingresos

11M

64M

Ventas

-3.2M

149M

P/B

Media del Sector

18.069

50.102

BPA

0.79

Margen de beneficios

42.663

Empleados

182

EBITDA

2M

83M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+3.45% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

285M

3.8B

Apertura anterior

31.29

Cierre anterior

31.32

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

156 / 344 Clasificación en Healthcare

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2026, 22:47 UTC

Ganancias

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 may 2026, 20:45 UTC

Ganancias

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 may 2026, 23:39 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 may 2026, 23:31 UTC

Charlas de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 may 2026, 23:17 UTC

Charlas de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 may 2026, 23:02 UTC

Charlas de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 may 2026, 22:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 may 2026, 21:12 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 may 2026, 21:00 UTC

Ganancias

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 may 2026, 20:57 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:55 UTC

Ganancias

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

28 may 2026, 20:48 UTC

Acciones populares

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 may 2026, 20:34 UTC

Ganancias

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 may 2026, 20:31 UTC

Ganancias

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 may 2026, 20:28 UTC

Ganancias

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 may 2026, 20:26 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Membership Fees $1.37B

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Net Sales $69.15B

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

3.45% repunte

Estimación a 12 Meses

Media 32.4 USD  3.45%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

1

Comprar

5

Mantener

0

Vender

Sentimiento

By Acuity

156 / 344 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
help-icon Live chat